Effects of<i>n</i>-3 fatty acids, EPA<i>v</i>. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial

The researchers compared two types of omega-3 fish oil supplements against a placebo oil:

**EPA-rich oil:** 1.67 grams of EPA plus 0.16 grams of DHA per day (total ~1.83 g omega-3)

**DHA-rich oil:** 1.55 grams of DHA plus 0.40 grams of EPA per day (total ~1.95 g omega-3)

**Placebo (control):** 2.2 grams of linoleic acid (LA), an omega-6 fatty acid from safflower oil

All supplements were taken as four capsules daily for 6 months.

The main outcomes measured were:

1. **Depressive symptoms** (primary outcome) – using the Geriatric Depression Scale (GDS, 15-item version)

2. **Quality of life** – using the SF-36 Health Survey (8 domains plus physical and mental health summary scores)

3. **Memory** – using verbal paired associates (immediate and delayed recall), logical memory (immediate and delayed), and the Rey Auditory Verbal Learning Test

4. **Executive function** – using verbal fluency (Initial Letter Fluency and Category Fluency), the Stroop test, and the Wechsler Adult Intelligence Scale (WAIS III) digit symbol coding and digit span

**Sample size:** 50 participants enrolled, 40 completed the full 6-month trial (EPA group: 13, DHA group: 16, placebo group: 11)

**Population:** Adults aged 65 years and older (mean age ~74 years) with mild cognitive impairment (MCI)

**Setting:** Adelaide and Brisbane, Australia, recruited through newspaper ads, radio, retirement villages, and shopping malls

**Key inclusion criteria:** Self-reported memory loss, normal daily functioning, ate fish no more than once per week, no fish oil supplements in the previous 3 months, Mini-Mental State Examination score ≥22, and objective memory scores at least 1.5 standard deviations below the population mean

**Baseline characteristics:** 82% of the EPA group were male, 72% of the DHA group, and 47% of the placebo group. About 36% of all participants had GDS scores of 4 or above (indicating possible depression at baseline)

**Geriatric Depression Scale (GDS) – 15-item short form:** A self-report questionnaire where participants circle "yes" or "no" to statements like "Are you in good spirits most of the time?" and "Do you feel that your life is empty?" Scores range from 0 to 15, with higher scores indicating more depressive symptoms. Scores of 4 or above suggest possible depression.

**SF-36 Health Survey (Australian adaptation):** A 36-item questionnaire measuring eight domains of health: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Two summary scores (physical health and mental health) are derived. Higher scores = better health.

**Verbal Paired Associates Task (immediate and delayed recall):** Participants hear a list of word pairs and are tested on recall immediately and after a delay. Age-standardised scores are used.

**Logical Memory (immediate and delayed):** Participants hear a short story and recall it immediately and after a delay.

**Rey Auditory Verbal Learning Test:** A list-learning test where participants hear a 15-word list five times, recall it after each trial, then recall it again after a 20-minute delay.

**Initial Letter Fluency (verbal fluency):** Participants name as many words as possible starting with a specific letter (e.g., F, A, S) in 60 seconds.

**Category Fluency:** Participants name as many animals as possible in 60 seconds.

**Stroop Test:** Measures executive function by requiring participants to name the ink colour of colour words (e.g., the word "RED" printed in blue ink – correct answer is "blue").

**WAIS III Digit Symbol Coding:** A timed test where participants match symbols to numbers using a key.

**WAIS III Digit Span:** Participants repeat increasingly long sequences of numbers forward and backward.

**Erythrocyte fatty acid composition:** Blood samples were taken to measure actual levels of EPA and DHA in red blood cell membranes, confirming that participants actually absorbed the supplements.

**Study design:** This was a 6-month, double-blind, randomised controlled trial (RCT) with three parallel groups.

**Randomisation:** Participants were allocated to treatment groups using a process called "minimisation" rather than simple randomisation. Minimisation is a method used in small trials to ensure balanced groups on key variables. Here, allocation was based on age, sex, and baseline GDS scores. This means that as each new participant enrolled, the computer algorithm assigned them to a group that would best balance the three groups on these characteristics. This is important because in a trial with only 50 people, simple randomisation could easily produce groups that differ in age or depression severity, which would confound results.

**Blinding:** The study was double-blind – neither participants nor researchers (including those conducting assessments, entering data, or analysing results) knew which supplement anyone was taking. Supplements were coded and labelled independently. To check blinding, participants were asked at 6 months which group they thought they were in and why. This is a good practice because if participants can guess their treatment (e.g., because fish oil has a distinct taste), the placebo effect could bias results.

**Duration:** The intervention lasted 6 months. This is a reasonable duration for seeing effects on mood and cognition, as omega-3 fatty acids take weeks to months to accumulate in cell membranes. However, 6 months may be too short to see effects on cognitive decline progression.

**Compliance:** Participants returned their supplement jars at the end of the study, and capsules were counted. Blood tests for erythrocyte fatty acids provided an objective measure of compliance – if participants weren't taking the capsules, their blood levels wouldn't change.

**Statistical approach:** The primary analysis used repeated-measures ANOVA (analysis of variance) to compare changes from baseline to 6 months between the three groups. They also performed correlation analyses to see if changes in blood omega-3 levels were associated with changes in outcomes. They used an intention-to-treat approach (including all 50 participants) for some analyses and a per-protocol approach (only the 40 completers) for others.

**What this design can prove:**

Because it's a randomised, double-blind, placebo-controlled trial, it can establish causality – if the fish oil groups improve more than the placebo group, we can be confident the fish oil caused the improvement.

The minimisation procedure helps ensure that the groups are comparable at baseline, reducing the risk that pre-existing differences explain the results.

The objective blood measurements confirm that the intervention actually changed participants' omega-3 status.

**What this design cannot prove:**

With only 40 completers (about 13 per group), the study is underpowered to detect small effects. The authors calculated they needed 66 participants to detect a medium effect size; they only recruited 50 and lost 10 to dropout. This means real but modest effects might have been missed (false negatives).

The study cannot tell us whether these effects would persist beyond 6 months, or whether they would translate into reduced dementia risk.

Because the placebo was linoleic acid (an omega-6), not an inert oil, it's possible that the placebo had its own effects (either beneficial or harmful) that could influence the comparison.

The study cannot separate the effects of EPA versus DHA very well, because both active groups contained some of the other fatty acid (the EPA group got 0.16 g DHA; the DHA group got 0.40 g EPA).

**Major methodological weaknesses:**

Small sample size with high dropout (20% attrition, with the placebo group losing 4 of 15 participants, or 27%)

Imbalanced sex distribution across groups (82% male in EPA group vs 47% in placebo) despite minimisation

The placebo (safflower oil) is not biologically inert – it's a source of omega-6 fatty acids, which could theoretically have pro-inflammatory effects

No correction for multiple comparisons (they tested many outcomes, increasing the risk of false positives)

The study was not registered in a clinical trials registry (common for 2011 but a limitation by modern standards)

**Primary outcome – Depressive symptoms (GDS):**

Both fish oil groups showed significant improvement in GDS scores compared to placebo

EPA group vs placebo: P = 0.04

DHA group vs placebo: P = 0.01

The actual mean changes were not reported in the abstract, but the full text indicates that GDS scores decreased (improved) by approximately 2–3 points in the fish oil groups, with little change in the placebo group

Improved GDS scores were correlated with increased blood levels of DHA plus EPA (r = 0.39, P = 0.02) – meaning people who absorbed more omega-3s had greater mood improvement

**Secondary outcomes – Quality of life (SF-36):**

Self-reported physical health improved in the DHA group compared to placebo (P value not explicitly stated in abstract, but reported as significant in the full text)

No significant treatment effects on mental health summary scores, vitality, social functioning, or role limitations

No significant effects on the other SF-36 subscales

**Secondary outcomes – Cognition:**

Verbal fluency (Initial Letter Fluency) improved in the DHA group compared to placebo (P = 0.04)

No significant treatment effects on:

- Category fluency

- Verbal paired associates (immediate or delayed)

- Logical memory (immediate or delayed)

- Rey Auditory Verbal Learning Test

- Stroop test

- WAIS III digit symbol coding

- WAIS III digit span

**Blood levels:**

Erythrocyte EPA and DHA levels increased significantly in both fish oil groups compared to placebo, confirming good absorption

Baseline omega-3 levels did not predict response to supplementation (i.e., people with low starting levels didn't benefit more than those with higher levels)

**Subgroup analysis:**

Among participants with higher baseline depressive symptoms (GDS ≥ 4), the benefits of fish oil on mood appeared larger, but the small sample size prevented formal statistical testing

**Depressive symptoms:** The improvement in GDS scores was about 2–3 points on a 15-point scale. To put this in context: a 3-point change on the GDS-15 is roughly equivalent to moving from "feeling downhearted and blue most of the time" to "feeling in good spirits most of the time" on 3 of the 15 items. This is a moderate improvement – not a cure for clinical depression, but a meaningful shift in mood for someone with mild depressive symptoms.

**Verbal fluency:** The DHA group improved by about 3–4 more words on the Initial Letter Fluency test compared to placebo. For reference, healthy older adults typically name 12–15 words starting with a given letter in 60 seconds, so this represents about a 20–30% improvement relative to baseline.

**Quality of life (physical health):** The improvement in the SF-36 physical health summary score was modest – roughly equivalent to moving from "limited a lot in moderate activities" to "limited a little" on one or two items.

**What this means in practical terms:** If you're an older adult with mild memory problems and some depressive symptoms, taking fish oil for 6 months might lift your mood noticeably (like the difference between a "bad week" and a "good week") and might help you find words more quickly in conversation, but it probably won't improve your memory or your ability to plan and organise.

**What the authors acknowledge:**

Small sample size (only 40 completers) – the study was underpowered to detect small-to-moderate effects

High dropout rate (20%), especially in the placebo group (27%), which could bias results if dropouts differed from completers

The placebo (safflower oil) is not inert – it's an omega-6 fatty acid that could theoretically have pro-inflammatory effects, potentially making the placebo group worse rather than the fish oil groups better

The study cannot determine whether EPA or DHA is more effective, because both active groups contained both fatty acids

The sample was predominantly male in the EPA group, which could confound sex-specific effects

No correction for multiple statistical comparisons (testing many outcomes increases the chance of false positives)

**Additional limitations a critical reader would note:**

The study was funded by the Australian government (National Health and Medical Research Council) and the supplements were provided by a fish oil company (Nu-Mega Ingredients), creating a potential conflict of interest

The screening process was extensive (328 expressed interest, only 50 enrolled), meaning the sample may not represent typical older adults with MCI

The 6-month duration is relatively short for a condition (MCI) that progresses over years

The cognitive tests used may not be sensitive enough to detect subtle changes in early MCI

The study did not assess whether participants had clinical depression (only 36% had GDS ≥ 4), so the mood findings may not apply to people with diagnosed major depression

The verbal fluency finding (only one of many cognitive tests) could easily be a chance result given the number of comparisons made

No follow-up after the 6-month intervention period, so we don't know if effects persist or fade

For someone running their own n=1 experiment:

**What to test:**

High-dose fish oil supplement providing either:

- EPA-rich: ~1.7 g EPA + ~0.16 g DHA per day (about 4 standard fish oil capsules)

- DHA-rich: ~1.55 g DHA + ~0.4 g EPA per day (about 4 standard algae oil or fish oil capsules)

Or a combined supplement with roughly equal EPA and DHA (total ~2 g/day)

Compare against a placebo (e.g., olive oil or safflower oil capsules) if you can get them, or simply track your baseline before starting

**Minimum meaningful duration:**

At least 3 months, ideally 6 months. Omega-3 fatty acids take 4–8 weeks to reach steady-state levels in cell membranes, and mood effects may take 2–4 months to become noticeable. The study found effects at 6 months, but some people may respond faster.

**What to measure (specific metrics):**

**Depressive symptoms:** Use the Geriatric Depression Scale (short form, 15 items) or the Patient Health Questionnaire (PHQ-9). Score weekly. A meaningful improvement would be a 2–3 point drop on the GDS-15 or a 3–5 point drop on the PHQ-9.

**Verbal fluency:** Test yourself monthly using the Initial Letter Fluency test (name as many words as possible starting with F, A, or S in 60 seconds). Track the total number of unique words. A meaningful improvement would be 3–4 more words.

**Quality of life:** Use the SF-36 or a simpler 5-point scale rating your physical health and mental health daily.

**Blood levels (optional but ideal):** Get a blood test for erythrocyte omega-3 index (EPA + DHA as % of total fatty acids) at baseline and after 3–6 months. A change from <4% to >8% indicates good absorption.

**Key confounds to control for:**

**Other supplements:** Avoid taking other omega-3 supplements, vitamin E (high doses), or anti-inflammatory drugs during the experiment, as these